Fluticasone Propionate/Salmeterol xinafoate

丙酸氟替卡松/昔萘酸沙美特罗

Report date: 2026/05/28 20:00:21

Base Information

Drug NameFluticasone Propionate/Salmeterol xinafoate
Drug Alias Name沙美特罗替卡松サルメテロールキシナホ酸塩・フルチカゾンプロピオン酸エステルSalmeterol Xinafoate and Fluticasone Propionate昔萘酸沙美特罗/丙酸氟替卡松Salmeterol xinafoate/fluticasone propionate +[32] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionBeta-2 adrenergic receptor agonistsGlucocorticoid receptor agonistsCytosolic phospholipase A2 agonists
TargetsBeta-2 adrenergic receptorGlucocorticoid receptorCytosolic phospholipase A2
Therapy Area/IndicationsEdemaGraves OphthalmopathyPulmonary Disease, Chronic Obstructive +[7] 
Global Approved IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Approved Indications in ChinaPulmonary Disease, Chronic ObstructiveAsthma
Original Approved Country/TerritorySweden
Original Approved Date1998/09/01
Country/TerritoryUnited StatesSwedenThailand +[13] 
CombinationsYes Fluticasone PropionateSalmeterol xinafoate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcUniversity Of Colorado DenverGlaxo Group Ltd +[4] 
Inactive CompaniesMylan Pharma Uk LtdHangzhou Zhixing Pharmaceutical Co LtdOriel Therapeutics Inc +[17] 
Active IndicationsEdemaPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsGraves OphthalmopathyBronchiolitis ObliteransRespiratory Tract Diseases +[4] 

Other Information

ATC CodeR03AK06
Related LinksKEGG